Bionoxx Inc. South Korea California

Bionoxx to Highlight Innovative Strategy for Addressing Immune-Related Diseases at 2024 BIO International Conference

About Bionoxx Products

BNX-IFS (Bionoxx's Immune Function States) is a novel technology that determines disease-related "immune dynamics" with circulating immune cells. Especially, BNX-IFS revealed that neutrophil plasticity may orchestrate T cell homeostasis. This has been partially proven in nonclinical disease models and clinical specimen from healthy as well as patients with immune-related diseases. Bionoxx is developing BNX-IFS as a tool for personalized immune modulation by optimizing T cell homeostasis in a variety of immune-mediated diseases.

OTS-412 is an investigational oncolytic virus designed to work with Bionoxx's immunomodulatory approach to destroy cancer cells. The immunomodulatory approach enhanced cancer-specific cytotoxic T cell immunity and induced synergistic anti-tumor effect with ICI in ICI-resistant nonclinical models.

About Bionoxx Inc.

Bionoxx Inc.(headquartered in South Korea) is an innovative biotechnology company pioneering neutrophil-directed T cell modulation to fight cancer and immune disorders. We are dedicated to maximizing clinical outcome for patients by tailoring immunotherapies with our novel technologies. Bionoxx is avidly seeking partners and collaborators in discovery and development efforts for cancer and immune-mediated diseases (e.g., acute viral infection, autoimmune diseases). For more information, please visit https://www.linkedin.com/company/bionoxx.

View original content:https://www.prnewswire.co.uk/news-releases/bionoxx-to-highlight-innovative-strategy-for-addressing-immune-related-diseases-at-2024-bio-international-conference-302152827.html